KORU Medical returns another small profit as Freedom infusion sales climb 11%
Quarterly sales reached $11.6m and gross margin improved, but the infusion-device maker cut its full-year margin forecast and tightened its revenue range.
KORU Medical Systems, the US maker of the Freedom system for subcutaneous infusion, reported third-quarter sales of $11.6m on 10 November, up 11.2% on the same period a year earlier. The quarter ended on 30 September 2026.
Profitability was modest but positive. KORU booked net income of $0.2m and adjusted EBITDA of $1.3m, and gross margin rose to 65.2%. The summary of the results presents this as the company's second profitable quarter in a row.
The outlook was more mixed. KORU now expects 2026 revenue of $48.0m to $48.5m, a tighter band than before. It also reduced its full-year gross margin forecast to 63% to 64%, which sits below the 65.2% achieved in the third quarter. Against that, it raised its year-end cash expectation to more than $8.0m.
The full release was not available, so the sources of growth, any change in product mix, the earlier guidance ranges and the reason for the lower margin forecast are not covered here.
Why it matters
- Double-digit quarterly growth suggests continued uptake of the Freedom platform, though KORU's drivers for it have not been disclosed.
- The lower full-year gross margin forecast is unexplained in the available material; further company detail would be needed to judge its cause.
- A higher year-end cash expectation is relevant to partners and customers assessing the financial standing of a device supplier.
Company's press release (SEC filing): KORU Medical Systems, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
